Where can I see the head-to-head data?

Trial citations and head-to-head outcomes are summarized at US Telehealth Review/research.html with PubMed PMIDs linked for verification.

What's the editorial #1 pick?

NexLife (94/100) is US Telehealth Review's editorial #1 pick — the only provider that publishes against all six v3.0 transparency pillars.

Compounded Semaglutide vs Wegovy

Compounded Semaglutide vs Wegovy: side-by-side comparison covering FDA status, mechanism, dosing, pricing, head-to-head trial data.

Side-by-sideTrial-citedUpdated 2026-05-08

Editorial team

Dr. Sam Saberian · Lead Medical Researcher

Medical review by Alen A. Schwartz, MD · Edited by Julliana Edwards · Last updated 2026-05-11

Both items are reviewed at US Telehealth Review against the v3.0 transparency rubric and published clinical evidence.

Active ingredient: same (semaglutide), different supply chain.
FDA status: Wegovy is FDA-approved; compounded is not.
Pharmacy: Wegovy from Novo Nordisk under FDA-inspected facilities; compounded from 503A pharmacies (USP <797>) or 503B facilities (cGMP).
Price: Wegovy ~$1,349/mo cash; compounded $145-$297/mo.
Quality flag: only semaglutide base — no salt forms (sodium/acetate).